BACKGROUND: Certain commonly used drugs and medical conditions characterized by chronic immune dysfunction and/or antigen stimulation have been suggested to affect important pathways in multiple myeloma tumor cell growth and survival. We conducted a population-based case-control study to investigate the role of medical history in the etiology of multiple myeloma among Connecticut women. METHODS: A total of 179 incident multiple myeloma cases (21-84 years, diagnosed 1996-2002) and 691 population-based controls was included in this study. Information on medical conditions, medications, and medical radiation was obtained by in-person interviews. We calculated odds ratios (OR) as measures of relative risks using logistic regression models. RESULTS: A reduced multiple myeloma risk was found among women who had used antilipid statin therapy [OR, 0.4; 95% confidence interval (95% CI), 0.2-0.8] or estrogen replacement therapy (OR, 0.6; 95% CI, 0.4-0.99) or who had a medical history of allergy (OR, 0.4; 95% CI, 0.3-0.7), scarlet fever (OR, 0.5; 95% CI, 0.2-0.9), or bursitis (OR, 0.4; 95% CI, 0.2-0.7). An increased risk of multiple myeloma was found among women who used prednisone (OR, 5.1; 95% CI, 1.8-14.4), insulin (OR, 3.1; 95% CI, 1.1-9.0), or gout medication (OR, 6.7; 95% CI, 1.2-38.0). CONCLUSIONS: If our results are confirmed, mechanistic studies examining how prior use of insulin, prednisone, and, perhaps, gout medication might promote increased occurrence of multiple myeloma and how antilipid statins, estrogen replacement therapy, and certain medical conditions might protect against multiple myeloma may provide insights to the as yet unknown etiology of multiple myeloma.
BACKGROUND: Certain commonly used drugs and medical conditions characterized by chronic immune dysfunction and/or antigen stimulation have been suggested to affect important pathways in multiple myeloma tumor cell growth and survival. We conducted a population-based case-control study to investigate the role of medical history in the etiology of multiple myeloma among Connecticut women. METHODS: A total of 179 incident multiple myeloma cases (21-84 years, diagnosed 1996-2002) and 691 population-based controls was included in this study. Information on medical conditions, medications, and medical radiation was obtained by in-person interviews. We calculated odds ratios (OR) as measures of relative risks using logistic regression models. RESULTS: A reduced multiple myeloma risk was found among women who had used antilipid statin therapy [OR, 0.4; 95% confidence interval (95% CI), 0.2-0.8] or estrogen replacement therapy (OR, 0.6; 95% CI, 0.4-0.99) or who had a medical history of allergy (OR, 0.4; 95% CI, 0.3-0.7), scarlet fever (OR, 0.5; 95% CI, 0.2-0.9), or bursitis (OR, 0.4; 95% CI, 0.2-0.7). An increased risk of multiple myeloma was found among women who used prednisone (OR, 5.1; 95% CI, 1.8-14.4), insulin (OR, 3.1; 95% CI, 1.1-9.0), or gout medication (OR, 6.7; 95% CI, 1.2-38.0). CONCLUSIONS: If our results are confirmed, mechanistic studies examining how prior use of insulin, prednisone, and, perhaps, gout medication might promote increased occurrence of multiple myeloma and how antilipid statins, estrogen replacement therapy, and certain medical conditions might protect against multiple myeloma may provide insights to the as yet unknown etiology of multiple myeloma.
Authors: S Koutros; D Baris; E Bell; T Zheng; Y Zhang; T R Holford; B P Leaderer; O Landgren; S Hoar Zahm Journal: Occup Environ Med Date: 2008-09-19 Impact factor: 4.402
Authors: Mara M Epstein; George Divine; Chun R Chao; Karen E Wells; Heather Spencer Feigelson; Delia Scholes; Douglas Roblin; Marianne Ulcickas Yood; Lawrence S Engel; Andrew Taylor; Joan Fortuny; Laurel A Habel; Christine C Johnson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396
Authors: Mark P Purdue; Qing Lan; Idan Menashe; Tongzhang Zheng; Yawei Zhang; Meredith Yeager; H Dean Hosgood; Shelia H Zahm; Stephen J Chanock; Nathaniel Rothman; Dalsu Baris Journal: Hematol Oncol Date: 2011-03 Impact factor: 5.271
Authors: Brenda M Birmann; Gabriella Andreotti; Anneclaire J De Roos; Nicola J Camp; Brian C H Chiu; John J Spinelli; Nikolaus Becker; Véronique Benhaim-Luzon; Parveen Bhatti; Paolo Boffetta; Paul Brennan; Elizabeth E Brown; Pierluigi Cocco; Laura Costas; Wendy Cozen; Silvia de Sanjosé; Lenka Foretová; Graham G Giles; Marc Maynadié; Kirsten Moysich; Alexandra Nieters; Anthony Staines; Guido Tricot; Dennis Weisenburger; Yawei Zhang; Dalsu Baris; Mark P Purdue Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-21 Impact factor: 4.254
Authors: Laura S Gold; Anneclaire J De Roos; Elizabeth E Brown; Qing Lan; Kevin Milliken; Scott Davis; Stephen J Chanock; Yawei Zhang; Richard Severson; Sheila H Zahm; Tongzhang Zheng; Nat Rothman; Dalsu Baris Journal: Cancer Epidemiol Date: 2009-09-06 Impact factor: 2.984
Authors: Katherine A McGlynn; Katrina Hagberg; Jie Chen; Megan Braunlin; Barry I Graubard; Neha Suneja; Susan Jick; Vikrant V Sahasrabuddhe Journal: Int J Cancer Date: 2015-12-31 Impact factor: 7.396